Did You Know?

Find answers to off-the-beaten path NSCLC trivia.

1 of 5

Bonnie J. Addario, founder and namesake of the Bonnie J. Addario Lung Cancer Foundation, was previously______

"CEO of an oil company"
"An elementary school teacher"
"A marathon runner"
2 of 5

The discovery of epidermal growth factor "EGF" in the 1960s would later win a Nobel Prize in Medicine and ultimately lead to the first biomarker-driven therapy for lung cancer. This discovery would not have been possible without____

"Whale oil"
"Tree bark"
"Salivary gland extract"
3 of 5

Biomarkers for lung cancer are mainly related to changes that happen in your____.

"Airway"
"Genes"
"Plasma"
4 of 5

There are currently more than ___ ongoing clinical trials examining the role of known biomarkers in patients with NSCLC.2

"50"
"400"
"1500"
5 of 5

Doctors used to believe lung cancer was one disease. Today, more than __ biomarkers that drive lung cancer have been identified in NSCLC alone.

"15"
"5"
"27"
  1. 1Armour A, Watkins C. The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer. Eur Respir Rev. 2010;19(117):186-196.
  2. 2ClinicalTrials.gov. 420 studies found for: KRAS OR EGFR OR ALK OR PIK3CA OR HER2 OR BRAF OR ROS OR RET OR NRAS OR MET | lung cancer. https://clinicaltrials.gov/ct2/results?term=KRAS+OR+EGFR+OR+ALK+OR+PIK3CA+OR+HER2+OR+BRAF+OR+ROS+OR+RET+OR+NRAS+OR+MET+&type=Intr&rslt=Without&recr=Recruiting&age_v=&gndr=&cond=non+small+cell+lung+cancer+&intr=&titles=&outc=&spons=&lead=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&rcv_s. Accessed May 26, 2017. PLUS https://clinicaltrials.gov/ct2/results?term=KRAS+OR+EGFR+OR+ALK+OR+PIK3CA+OR+HER2+OR+BRAF+OR+ROS+OR+RET+OR+NRAS+OR+MET&type=Intr&rslt=Without&recr=Active%2C+not+recruiting&age_v=&gndr=&cond=non+small+cell+lung+cancer&intr=&titles=&outc=&spons=&lead=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&rcv_s=&rcv_e=&lup_s=&lup_e=. Accessed May 26, 2017. PLUS https://clinicaltrials.gov/ct2/results?term=KRAS+OR+EGFR+OR+ALK+OR+PIK3CA+OR+HER2+OR+BRAF+OR+ROS+OR+RET+OR+NRAS+OR+MET&type=Intr&rslt=Without&recrs=a&age_v=&gndr=&cond=non+small+cell+lung+cancer&intr=&titles=&outc=&spons=&lead=&id=&cntry1=&state1=&cntry2=&state2=&cntry3=&state3=&locn=&rcv_s=&rcv_e=&lup_s=&lup_e=. Accessed May 26, 2017.
  3. 3Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1000 patients with lung adenocarcinoma: the NCI’s Lung Cancer Mutation Consortium, (LCMC). J Clin Oncol. 2011;29(suppl; abstr CRA7506). Page 10. http://meetinglibrary.asco.org/content/81670-102. Accessed August 1, 2017.
  4. 4Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378-381. doi:10.1038/nm.2558.